尿路感染症に対するFuradantinの使用経験

Abstract

1) Furadantin was used in 47 patients with various urinar y tract infections. The dosage was 100 mg four times a day for seven days in average. Bacteriological and clinical cure were obtained in 12 patients, improvement in 19 patients but no change was observed in 16 patients. 2) Furadantin was highly effective to the patients with Escherichia or Staphylococcus infection but was not effective to those with Pseudomonas or Candida infection. 3) Unpleasant side-effects developed in 9 of 47 patients. The r e actions were mostly mild and gastrointestinal but severe headache, tinnitus, nausea and vomiting developed in an exceptional patient and, was forced to discontinue the dosage. 4) Furadantin Sensi-Disc test, was performed on 165 bacterial strains isolated from the patients with urinary tract infection and was found to be highly sensitive to Staphylococcus, Escherichia, Streptococcus viridans and Streptococcus hemolytics, relatively sensitive to Streptococcus faecalis, Corynebacterium, Klebsiella, Alkaligenes faecalis, Citrobacter etc., and resistant to Pseudomonas, Proteus, Cloaca and Candida. 5) Furadantin was found to be sensitive to 5 6% of the total 165 bacterial strains by the sensi-disc test, and when it was compared to those of the other antibiotics or chemotherapeutics, it was next to Kanamycin (73%) and was superior to Chloromycetin (49%), Erythromycin (34%), Streptomycin (30%), Terramycin (27%), Penicillin (27%), and Sulfisoxazol (6%). 6) The excretory concentration of Furadantin into the urine following the oral administration of Furadantin 100 mg was determined by bacteriological assay and it demonstrated the maximun concentration in three hours, then a rapid fall in the next hour and below the minimum inhibitory level after five hours. As a conclusion, we believe that Furadantin is an effective chemotherapeutic agent for combating urinary tract infections.